title: Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study.
abstract: Natalizumab has been shown to be effective in pivotal clinical trials in multiple sclerosis; however, the patients in whom treatment is indicated in clinical practice have a different clinical profile from those included in the clinical trials. The aim of this study is therefore to collect data on natalizumab use in everyday clinical practice in Spain. The 86 participating centers throughout Spain submitted data on disease characteristics at baseline and after treatment. Valid data were available for 1,364 patients (69.3% women, 86.9% with relapsing–remitting disease).
authors.affiliation: Institute of Clinical Neurosciences, Carlos Haya Regional University Hospital, Avenida Carlos Haya s/n, 29010 Málaga, Spain. oscar.fernandez.sspa@juntadeandalucia.es
authors.forename: O
authors.initials: O
authors.lastname: Fernández
authors.forename: C
authors.initials: C
authors.lastname: Oreja-Guevara
authors.forename: R
authors.initials: R
authors.lastname: Arroyo
authors.forename: G
authors.initials: G
authors.lastname: Izquierdo
authors.forename: J L
authors.initials: JL
authors.lastname: Pérez
authors.forename: X
authors.initials: X
authors.lastname: Montalban
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology; D000069442:Natalizumab; D019370:Observation; D013030:Spain / Q000453:epidemiology; D018709:Statistics, Nonparametric; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab